Premium keratin KeraNetics specializes in purified, human-derived keratin for wound healing, presenting a unique material proposition that could be pitched to wound care and oncology departments seeking advanced RD management options.

Regulatory ready KeraStat Cream is FDA-cleared and already available Rx only, suggesting a near-term entry point for hospital GPOs, distributors, and dermatology clinics looking to add evidence-backed radiation dermatitis solutions.

Clinical demand Radiation dermatitis management represents a targeted clinical need with a defined patient population; sales efforts can focus on oncology centers, radiation therapy clinics, and post-treatment wound care programs.

Growth potential With revenue in the low-to-mid single digits and a funding position around twelve million, there is room to scale through expanded payer conversations, clinical studies, and broader market adoption in wound care and dermatology.

Tech & reach Leverage digital渠道 and partner networks, including LinkedIn advertising and healthcare-focused platforms, to reach decision-makers in hospitals, clinics, and research institutions, accelerating awareness and trial opportunities.